Connecticut Medicaid P&T Meeting Minutes May 8, 2013

Transcription

1 The meeting started at 6:14pm Attendance Connecticut Medicaid P&T Meeting Minutes May 8, 2013 Present Members: Carl Sherter, MD Charles Thompson, MD Emmett Sullivan, RPh Stella Cretella Hilda Slivka, MD Cynthia Conrad, MD Manage Nissanka, MD Kevin Chamberlin, PharmD Karen McMillan RN Jeffrey Kamradt, MD Absent Members: Mark Defrancesco, MD Angelo DeFazio, RPh Elizabeth Rodriguez, RN Andrew Lustbader, MD Eric Einstein, MD DSS: Evelyn Dudley Jason Gott, RPh James Zakszewski, RPh HP/Provider Synergies: Deborah Gallagher Kathy Novak, RPh Mark Synol, RPh Jason Young PharmD Margaret Stroczkowski Melissa Chandler Opening remarks: Dr. Carl Sherter thanked the attendees for coming and called meeting to order at 6:14pm. Dr. Sherter introduced Dr. Jeffrey Kamradt MD (Practicing Physician, Oncologist) and Karen McMillan RN (Practicing Visiting Nurse, Adult) as the two new appointed members to the P&T committee. Evelyn Dudley with DSS commented on a pending change to the prior authorization process for PPIs requiring patients to have trialed a preferred product before obtaining a non-pdl PPI, as evidenced by presence of a past claim for a preferred PPI. Target effective date for this change is 7/1/13. DSS suggested potential for future step therapy type processes for other medication classes, excluding mental health, pending current legislation. Dr. Sherter and other members of committee voiced disagreement with expanding step therapy to other classes but agreed to discuss amongst the committee at a date following approval of legislation. Public Presentations: Antibiotics, inhaled Cayston and TOBI Colony Stimulating Factors Neulasta Dr. Sam Pope MD CT CF Foundation Michael Masamitsu PharmD Amgen

2 Hypoglycemics, Incretin mimetics/enhancers - GLP-1 Receptor Agonists Dr. Elgis Bogdanovics MD - Victoza Justin Bakhshai PharmD Novo Irritable Bowel Syndrome Linzess Dr. Peter Buch MD Multiple Sclerosis Agents - Gilenya Dr. David Greco MD - Gilenya Thomas Algozzine PharmD Novartis Platelet Aggregation Inhibitors -Effient and Brilinta Dr. Ricardo Cordido MD -Brilinta Dr. Daniel Dadourian MD AstraZeneca Anticoagulants -Eliquis Eduard Goldenberg PharmD BMS -Xarelto Arlene Price PharmD Janssen Antiparasitics, Topical Sklice Stephen Smith, Sanofi Pasteur Growth Hormone Genotropin Aniello Marotta PharmD Pfizer Opiate Dependence Treatments Suboxone Film Dale Wallington MD Reckitt Benckinser The rest of the scheduled speakers waived their right to speak since their product was recommended as preferred on the PDL. Therapeutic Class Reviews: Antiemetics/Antivertigo Agents No significant clinical updates from Provider Synergies. Dr. Cynthia Conrad motioned to accept the PDL recommendations as presented with Emmett Sullivan seconding the motion. This motion was passed unanimously. ON Medicaid PDL: EMEND (ORAL), EMEND PACK (ORAL), MARINOL (ORAL), ONDANSETRON ODT (ORAL), ONDANSETRON SOLUTION (ORAL), ONDANSETRON TABLETS (ORAL) OFF Medicaid PDL: ANZEMET (ORAL), CESAMET (ORAL), DRONABINOL (ORAL), GRANISETRON (ORAL) GRANISOL SOLUTION (ORAL), SANCUSO (TRANSDERMAL), ZOFRAN ODT (ORAL), ZOFRAN TABLETS (ORAL), ZOFRAN SOLUTION (ORAL), ZUPLENZ (ORAL) Antibiotics, Inhaled Kathy Novak informed committee there are no significant clinical updates for this class. The TobiPodhaler will be reviewed next year. Dr. Sam Pope from the CT CF Foundation gave public testimony advocating PDL status for both TOBI and Cayston. Dr. Cynthia Conrad motioned to accept the recommendations along with the addition of Cayston to the PDL. Dr. Hilda Slivka seconded this motion and the motion was passed unanimously. ON Medicaid PDL: CAYSTON (INHALATION, TOBI (INHALATION) OFF Medicaid PDL: NONE Colony Stimulating Factors There were no significant clinical updates for this class. Michael Masamitsu PharmD from Amgen provided public testimony advocating for the addition of Neulasta to the Medicaid PDL. Dr. Jeffrey M Kamradt strongly motioned to accept the recommendations as presented along with the addition of

3 Neulasta to the PDL. His motion was seconded by Stella Cretella and the committee unanimously approved this motion. ON Medicaid PDL: NEULASTA (INJECTION), NEUPOGEN DISP SYRIN (INJECTION), NEUPOGEN VIAL (INJECTION) OFF Medicaid PDL: LEUKINE (INJECTION) Erythropoiesis Stimulating Proteins Kathy Novak informed of new medication Omontys which entered the market in April 2012, but was voluntarily recalled from market in February 2013 and will not be reviewed. Emmett Sullivan motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded this motion and the committee approved the motion unanimously. ON Medicaid PDL: ARANESP VIAL (INJECTION), ARANESP DISP SYRIN (INJECTION), PROCRIT (INJECTION) OFF Medicaid PDL: EPOGEN (INJECTION) Hypoglycemics, Incretin Mimetics/Enhancers Kathy Novak informed committee of new medications to class: Janumet XR, Nesina, Kazano, and Oseni. Dr. Elgis Bogdanovics provided public testimony advocating for the inclusion of GLP-1 Receptor Agonists to the PDL. Justin Bakhshai PharmD from Novo provided testimony requesting for the committee s inclusion of Victoza to the PDL. Kevin Chamberlin motioned to accept the recommendations along with the addition of Victoza to the PDL and his motion was seconded by Dr. Cynthia Conrad. This motion was passed unanimously. ON Medicaid PDL: JANUMET (ORAL), JANUMET XR (ORAL), JANUVIA (ORAL), JENTADUETO (ORAL), TRADJENTA (ORAL), VICTOZA (SUBCUTANE.) OFF Medicaid PDL: BYDUREON (SUBCUTANE.), BYETTA PENS (SUBCUTANE.), JUVISYNC (ORAL), KAZANO (ORAL), KOMBIGLYZE XR (ORAL), NESINA (ORAL), ONGLYZA (ORAL), OSENI (ORAL), SYMLIN PENS (SUBCUTANE.) Irritable Bowel Syndrome Kathy Novak advised that this is a new medication class for review. Linzess and Amitiza are the only products in the class and both are indicated for chronic idiopathic constipation and IBS with constipation. Dr. Peter Buch spoke briefly to the committee about the impact of IBS and benefits of treatment with Linzess. Dr. Hilda Slivka motioned to accept recommendations as presented for this class and Dr. Charles Thompson seconded. This motion was passed unanimously. ON Medicaid PDL: AMITIZA (ORAL), LINZESS (ORAL) OFF Medicaid PDL: NONE Multiple Sclerosis Agents

4 Kathy Novak provided committee with information regarding new medication to class, Aubagio(teriflunomide). Dr. David Greco provided testimony advocating for the inclusion of Gilenya on the PDL. Thomas Algozzine PharmD with Novartis provided additional testimony advocating for Gilenya. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class and was seconded by Dr. Manage Nissanka. This motion was passed unanimously. ON Medicaid PDL: AVONEX (INTRAMUSC.), AVONEX PEN (INTRAMUSC), BETASERON (SUBCUTANE.), COPAXONE (SUBCUTANE), REBIF (SUBCUTANE.) OFF Medicaid PDL: AMPYRA (ORAL), AUBAGIO (ORAL), EXTAVIA KIT (SUBCUTANE.), EXTAVIA VIAL (SUBCUTANE.), GILENYA (ORAL) Platelet Aggregation Inhibitors There we no clinical updates from Provider Synergies. Dr. Ricardo Cordido presented public testimony advocating inclusion of Brilinta and Effient on the Medicaid PDL. Dr. Daniel Dadourian with AstraZeneca also provided testimony in favor of Brilinta for the PDL. Dr. Hilda Slivka motioned to accept the recommendations presented along with the addition of Brilinta to the PDL and her motion was seconded by Dr. Manage Nissanka. This motion was passed unanimously. ON Medicaid PDL: AGGRENOX (ORAL), BRILINTA (ORAL), CLOPIDOGREL (ORAL), DIPYRIDAMOLE (ORAL) OFF Medicaid PDL: (ORAL) EFFIENT (ORAL), PERSANTINE (ORAL), PLAVIX (ORAL), TICLOPIDINE Anticoagulants Kathy Novak advised on new contraindication for use of Pradaxa with mechanical heart valves. Eduard Goldenber PharmD with BMS provided testimony and requested the committee s inclusion of Eliquis to the PDL. Arlene Price PharmD with Janssen spoke regarding new indications and dosing on Xarelto. Stella Cretella motioned to accept recommendations as presented but her motion was not seconded by a committee member. Dr. Hilda Slivka motioned to accept the recommendations as presented along with the addition of Eliquis to the PDL. Dr. Manage Nissanka seconded her motion. All committee members voted in favor with the exception of Stella Cretella who opposed this motion. The motion passed 9-1. ON Medicaid PDL: ELIQUIS (ORAL), FRAGMIN DISP SYRIN (SUBCUTANE.), FRAGMIN VIAL (SUBCUTANE.), LOVENOX SYRINGE (SUBCUTANE.), LOVENOX VIAL (SUBCUTANE.), PRADAXA (ORAL), WARFARIN (ORAL), XARELTO (ORAL) OFF Medicaid PDL: ARIXTRA (SUBCUTANE.), COUMADIN (ORAL), ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS), ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS), ENOXAPARIN SYRINGE (SUBCUTANE.), ENOXAPARIN SYRINGE (AUTH GEN) (SUBCUTANE.), FONDAPARINUX (SUBCUTANE) Antiparasitics, Topical There were no clinical updates from provider synergies for this class. Stephen Smith from Sanofi Pasteur provided public testimony requesting the committee s inclusion of Sklice on the PDL for this medication

5 class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded this motion and the committee unanimously approved the motion. At this time the late arrival of Eric Wittbrodt PharmD with Takeda, scheduled to speak earlier in the agenda regarding Nesina, was announced to the committee. The committee chose not to revisit that topic and denied opportunity to speak. ON Medicaid PDL: EURAX CREAM (TOPICAL), NATROBA (TOPICAL), PERMETHRIN (TOPICAL), ULESFIA (TOPICAL) OFF Medicaid PDL: EURAX LOTION (TOPICAL), LINDANE LOTION (TOPICAL), LINDANE SHAMPOO (TOPICAL), MALATHION (TOPICAL), MALATHION BRAND (TOPICAL) OVIDE (TOPICAL), SKLICE (TOPICAL), SPINOSAD (TOPICAL) Bladder Relaxant Preparations Kathy Novak introduced a new medication to the class, Myrbetriq(mirabegron), a beta-3 agonist. She also advised Oxytrol (oxybutynin transdermal patch) will be available OTC for women >18 years of age. Kevin Chamberlin motioned to accept the recommendations for this class as presented. His motion was seconded by Emmett Sullivan and the motion was passed unanimously. ON Medicaid PDL: OXYBUTYNIN ER (ORAL), OXYBUTYNIN SYRUP (ORAL), OXYBUTYNIN TABLET (ORAL), TOVIAZ (ORAL), VESICARE (ORAL) OFF Medicaid PDL: DETROL (ORAL), DETROL LA (ORAL), DITROPAN XL (ORAL), ENABLEX (ORAL), FLAVOXATE (ORAL), GELNIQUE (TRANSDERM.), GELNIQUE GEL MD PMP (TRANSDERMAL), MYRBETRIQ (ORAL) OXYTROL (TRANSDERM.), SANCTURA (ORAL), SANCTURA XR (ORAL), TOLTERODINE (ORAL), TROSPIUM (ORAL), TROSPIUM ER (ORAL) Growth Hormone There were no new clinical updates for this class of medications. Aniello Marotta PharmD with Pfizer spoke to the committee regarding Genotropin and requested its inclusion on the Medicaid PDL. Dr. Hilda Slivka motioned to include Genotropin along with the recommendations for this class. Dr. Cynthia Conrad seconded this motion and the motion was passed unanimously. ON Medicaid PDL: GENOTROPIN CARTRIDGE (INJECTION), GENOTROPIN DISP SYRIN (INJECTION), NORDITROPIN PEN (INJECTION), NUTROPIN AQ CARTRIDGE (INJECTION), NUTROPIN AQ VIAL (INJECTION), NUTROPIN VIAL (INJECTION) OFF Medicaid PDL: HUMATROPE CARTRIDGE (INJECTION), HUMATROPE VIAL (INJECTION), OMNITROPE CARTRIDGE (INJECTION), OMNITROPE VIAL (INJECTION), SAIZEN CARTRIDGE (INJECTION), SAIZEN VIAL (INJECTION), SEROSTIM VIAL (INJECTION), TEV-TROPIN VIAL (INJECTION), ZORBTIVE VIAL (INJECTION) Bone Resorption Suppression and Related Agents Kevin Chamberlin advised the committee of a recent FDA communication recommending against the use of Miacalcin for osteoporosis. Kathy Novak noted that the indication had not been removed. Kevin

6 Chamberlin motioned to approve the recommendations for this class with the removal of Miacalcin from the PDL. The motion was seconded by Dr. Hilda Slivka and the motion passed unanimously. ON Medicaid PDL: ALENDRONATE TABLETS (ORAL) OFF Medicaid PDL: ACTONEL (ORAL), ATELVIA (ORAL), BINOSTO (ORAL), BONIVA (ORAL), CALCITONIN SALMON (NASAL), ETIDRONATE DISODIUM (ORAL), EVISTA (ORAL), FORTEO (SUBCUTANE.), FORTICAL (NASAL), FOSAMAX (ORAL), FOSAMAX PLUS D (ORAL), IBANDRONATE TABLETS (ORAL), MIACALCIN (NASAL), PROLIA (SUBCUTANE.) Hepatits C Agents. No significant clinical updates were provided from Provider Synergies. Dr. Cynthia Conrad motioned to accept the recommendations as presented. Kevin Chamberlin seconded the motion and the committee passed the motion unanimously. ON Medicaid PDL: INCIVEK (ORAL), PEGASYS KIT (SUBCUTANE.), PEGASYS PROCLICK (SUB- Q), PEGASYS SYRINGE (SUB-Q), PEGASYS VIAL (SUBCUTANE.) RIBAVIRIN TABLET (ORAL), VICTRELIS (ORAL) OFF Medicaid PDL: INFERGEN (SUBCUTANE.), PEG-INTRON (SUBCUTANE.), PEG-INTRON REDIPEN (SUBCUTANE.), REBETOL SOLUTION (ORAL), RIBAPAK (ORAL), RIBASPHERE 400 MG (ORAL), RIBASPHERE 600 MG (ORAL), RIBAVIRIN CAPSULE (ORAL) Hypoglycemics, Insulin and Related Agents No new clinical updates were discussed by Provider Synergies for this class. The committee discussed the recommendation to remove Lantus Solostar pens from the PDL. Dr. Sherter commented on potential difficulties changing well controlled patients long acting insulin product. Many committee members voiced agreement. Dr. Charles Thompson motioned to accept recommendations for this class along with the addition of Lantus Solostar Pens. The motion was seconded by Dr. Hilda Slivka. This motion passed unanimously. ON Medicaid PDL: HUMALOG CARTRIDGE (SUBCUTANE.), HUMALOG MIX PEN (SUBCUTANE.), HUMALOG MIX VIAL (SUBCUTANE.), HUMALOG PEN (SUBCUTANE.), HUMALOG VIAL (SUBCUTANE.), HUMULIN 500 U/M VIAL (SUBCUTANE.), HUMULIN 70/30 PEN OTC (SUBCUTANE.), HUMULIN 70/30 VIAL OTC (SUBCUTANE.), HUMULIN PEN OTC (SUBCUTANE.), HUMULIN VIAL OTC (SUBCUTANE.), LANTUS CARTRIDGE (SUBCUTANE.), LANTUS SOLOSTAR PEN (SUBCUTANE.), LANTUS VIAL (SUBCUTANE.), LEVEMIR PENS (SUBCUTANE.), LEVEMIR VIAL (SUBCUTANE.), NOVOLIN 70/30 VIAL OTC (SUBCUTANE.), NOVOLOG CARTRIDGE (SUBCUTANE.), NOVOLOG MIX PEN (SUBCUTANE.), NOVOLOG MIX VIAL (SUBCUTANE.), NOVOLOG PEN (SUBCUTANE.), NOVOLOG VIAL (SUBCUTANE.) OFF Medicaid PDL: APIDRA SOLOSTAR PEN (SUB-Q), APIDRA VIAL (SUBCUTANE.) Opiate Dependence Treatments Kathy Novak informed of Reckitt Benckiser voluntarily recalling brand Suboxone due to risks of pediatric exposure. Naltrexone was added to category and two new generics: buprenorphine/naloxone tablets

7 (generic Suboxone SL) and naltrexone tablets (generic Revia). Dr. Dale Wallington MD with Reckitt Benckinser provided information on the Suboxone Film. He noted the advantage of reduced risk of accidental exposure by children since medication packaging is more child resitant. Kevin Chamberlin motioned to accept the recommendations for this drug class and Dr. Manage Nissanka seconded the motion. The motion passed unanimously. ON Medicaid PDL: NALTREXONE (ORAL), SUBOXONE FILM (SUBLINGUAL) OFF Medicaid PDL: BUPRENORPHINE HCL (SUBLINGUAL), BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL), SUBOXONE TABLETS (SUBLINGUAL), VIVITROL (INTRAMUSC) PAH Agents, Oral and Inhaled There were no new clinical updates from Provider Synergies. Kevin Chamberlin motioned to accept the recommendations for this class as presented. The motion was seconded by Karen McMillan and was passed unanimously by the committee. ON Medicaid PDL: ADCIRCA (ORAL), LETAIRIS (ORAL) SILDENAFIL (ORAL), TRACLEER (ORAL), VENTAVIS (INHALATION) OFF Medicaid PDL: REVATIO (ORAL), TYVASO (INHALATION) Pancreatic Enzymes Kathy Novak informed the committee of new products to class: Petzye, Ultresa, and Viokace. Dr. Charles Thompson motioned to accept the recommendations as presented for this drug class. Dr. Hilda Slivka seconded this motion and it was passed unanimously by the committee. ON Medicaid PDL: CREON (ORAL), PANCRELIPASE (ORAL), ZENPEP (ORAL) OFF Medicaid PDL: PANCREAZE (ORAL), PERTZYE (ORAL), ULTRESA (ORAL), VIOKACE (ORAL) Acne Agents, Topical Kathy Novak commented on new sodium sulfacetamide/sulfur product SSS 10-4, and new benzoyl peroxide products: BenzePro Foam, Effaclar Duo, and OC8. Dr. Cynthia Conrad motioned to accept the PDL recommendations for this class as presented with Dr. Manage Nissanka seconding. The motion was passed unanimously. ON Medicaid PDL: AZELEX (TOPICAL), BENZACLIN W/PUMP (TOPICAL), BENZOYL PEROXIDE CLEANSER (TOPICAL), BENZOYL PEROXIDE GEL (TOPICAL), CLINDAMYCIN PHOSPHATE GEL (TOPICAL), CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL), CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL), DIFFERIN CREAM (TOPICAL), DIFFERIN GEL (TOPICAL), DIFFERIN LOTION (TOPICAL), DUAC (TOPICAL), ERYTHROMYCIN GEL (TOPICAL), ERYTHROMYCIN SOLUTION (TOPICAL), RETIN-A MICRO (TOPICAL) OFF Medicaid PDL: ACANYA W/PUMP (TOPICAL), ACNE SPOT TREATMENT (TOPICAL), ACZONE (TOPICAL), ADAPALENE CREAM (TOPICAL), ADAPALENE GEL (TOPICAL), AKNE-MYCIN (TOPICAL), ATRALIN (TOPICAL), AVAR CLEANSER (TOPICAL), AVAR LS (TOPICAL), AVAR-E (TOPICAL), AVAR-E LS (TOPICAL), BENZACLIN (TOPICAL), BENZAMYCIN (TOPICAL), BENZEFOAM (TOPICAL), BENZEFOAM ULTRA (TOPICAL), BENZEPRO (TOPICAL), BENZOYL

8 PEROXIDE KIT (TOPICAL), BENZOYL PEROXIDE MICROSPHERES CLEANSER (TOPICAL), BENZOYL PEROXIDE TOWELETTE (TOPICAL), BP 10-1 (TOPICAL), CERISA (TOPICAL), CLARIFOAM EF (TOPICAL), CLENIA (TOPICAL), CLEOCIN T GEL (TOPICAL), CLEOCIN T LOTION (TOPICAL), CLEOCIN T MED. SWAB (TOPICAL), CLEOCIN T SOLUTION (TOPICAL), CLINDACIN PAC KIT (TOPICAL), CLINDAGEL (TOPICAL), CLINDAMYCIN / BENZOYL PEROXIDE (BENZACLIN) (TOPICAL), CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL), CLINDAMYCIN PHOSPHATE FOAM (TOPICAL), CLINDAMYCIN PHOSPHATE LOTION (TOPICAL), EPIDUO (TOPICAL), ERYTHROMYCIN MED. SWAB (TOPICAL), ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL), EVOCLIN (TOPICAL), INOVA (TOPICAL), INOVA 4/1 (TOPICAL), INOVA 8/2 (TOPICAL), KLARON (TOPICAL), OVACE PLUS CREAM ER (TOPICAL), OVACE PLUS SHAMPOO (TOPICAL), OVACE PLUS WASH (TOPICAL), PACNEX HP (TOPICAL), PACNEX LP (TOPICAL), PANOXYL-8 OTC (TOPICAL), RETIN-A CREAM (TOPICAL), RETIN-A GEL (TOPICAL), RETIN-A MICRO PUMP (TOPICAL), SSS 10-4 (TOPICAL), SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL), SULFACETAMIDE / SULFUR CLEANSER (TOPICAL), SULFACETAMIDE / SULFUR CLEANSING CLOTHS (TOPICAL), SULFACETAMIDE / SULFUR LOTION (TOPICAL), SULFACETAMIDE / SULFUR MED. PAD (TOPICAL), SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL), SULFACETAMIDE CLEANSER (TOPICAL), SULFACETAMIDE SODIUM/SULFUR (TOPICAL), SULFACETAMIDE SODIUM/SULFUR CREAM (TOPICAL), SULFACETAMIDE SUSPENSION (TOPICAL), SULPHO-LAC (TOPICAL), SUMADAN KIT (TOPICAL), SUMADAN WASH (TOPICAL), SUMAXIN CLEANSER (TOPICAL), SUMAXIN CP KIT (TOPICAL), SUMAXIN MED. PAD (TOPICAL), SUMAXIN TS SUSPENSION (TOPICAL), TAZORAC CREAM (TOPICAL), TAZORAC GEL (TOPICAL), TRETINOIN CREAM (TOPICAL), TRETINOIN GEL (TOPICAL), VELTIN (TOPICAL), ZIANA (TOPICAL) Analgesics, Narcotic Long Acting Kathy Novak states that REMS was introduced in July 2012 for long-acting opiates due to risk of abuse. FDA safety warning issued regarding misuse of Opana ER increasing risk of thrombocytopenic purpura and kidney failure when individuals crush the medication and inject it. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Cynthia Conrad seconded this motion. The motion passed unanimously. ON Medicaid PDL: FENTANYL (TRANSDERM), KADIAN (ORAL), METHADONE CONC (ORAL), METHADONE SOL TABLET (ORAL), METHADONE SOUTION (ORAL), METHADONE TABLET (ORAL), MORPHINE ER TABLET (ORAL), TRAMADOL ER (ORAL) OFF Medicaid PDL: AVINZA (ORAL), BUTRANS (TRANSDERM), CONZIP (ORAL), DURAGESIC MATRIX (TRANSDERM.), EXALGO (ORAL), MORPHINE ER CAPSULE (KADIAN) (ORAL), MS CONTIN (ORAL), NUCYNTA ER (ORAL), OPANA ER (ORAL), OXYCONTIN (ORAL), OXYMORPHONE ER (ORAL), TRAMADOL ER (GENERIC RYZOLT ER) (ORAL), ULTRAM ER (ORAL) Analgesics, Narcotic Short Acting Kathy Novak commented on reformulations of Vicodin containing lower acetaminophen amounts and new product Subsys (sublingual fentanyl). Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class. Her motion was seconded by Kevin Chamberlin and the motion passed unanimously. ON Medicaid PDL: APAP / CODEINE ELIXIR (ORAL), APAP / CODEINE TABLET (ORAL), BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL), BUTALBITAL COMPOUND W/CODEINE (ORAL), BUTORPHANOL TARTRATE (NASAL), CODEINE (ORAL), DIHYDROCODEINE / APAP / CAFFEINE (ORAL), HYDROCODONE / APAP CAPSULE (ORAL), HYDROCODONE / APAP SOLUTION (ORAL), HYDROCODONE / APAP TABLET (ORAL), HYDROCODONE / IBUPROFEN (ORAL),

9 HYDROMORPHONE TABLET (ORAL), MORPHINE CONC SOLUTION (ORAL), MORPHINE IR TABLET (ORAL), MORPHINE SOLUTION (ORAL), MORPHINE SUPPOSITORIES (RECTAL), OXYCODONE / APAP CAPSULE (ORAL), OXYCODONE / APAP TABLET (ORAL), OXYCODONE / ASA (ORAL), OXYCODONE / IBUPROFEN (ORAL), OXYCODONE CAPSULE (ORAL), OXYCODONE SOLUTION (ORAL), OXYCODONE TABLET (ORAL), PENTAZOCINE / APAP (ORAL), ROXICET SOLUTION (ORAL), TRAMADOL (ORAL), TRAMADOL / APAP (ORAL) OFF Medicaid PDL: ABSTRAL (SUBLINGUAL), ACTIQ (BUCCAL), CAPITAL W-CODEINE (ORAL), CARISOPRODOL COMPOUND-CODEINE (ORAL), CODEINE SOLUTION (ORAL), DEMEROL (ORAL), DILAUDID LIQUID (ORAL), DILAUDID TABLETS (ORAL), FENTANYL (BUCCAL), FENTORA (BUCCAL), FIORICET / CODEINE (ORAL), FIORINAL / CODEINE (ORAL), HYCET (ORAL), HYDROMORPHONE LIQUID (ORAL), HYDROMORPHONE SUPPOSITORIES (RECTAL), IBUDONE (ORAL), LEVORPHANOL (ORAL), LORCET (ORAL), LORTAB (ORAL), MAGNACET (ORAL), MEPERIDINE SOLUTION (ORAL), MEPERIDINE TABLET (ORAL), NORCO (ORAL), NUCYNTA (ORAL), ONSOLIS (BUCCAL), OPANA (ORAL), OXECTA (ORAL), OXYCODONE / ASA BRAND (ORAL), OXYCODONE CONC (ORAL), OXYMORPHONE (ORAL), PENTAZOCINE / NALOXONE (ORAL), PERCOCET (ORAL), PERCODAN (ORAL), PRIMLEV (ORAL), REPREXAIN (ORAL), ROXICODONE TABLET (ORAL), RYBIX ODT (ORAL), SUBSYS (SUBLINGUAL), SYNALGOS-DC (ORAL), TYLENOL-CODEINE (ORAL), ULTRACET (ORAL), ULTRAM (ORAL), VICODIN (ORAL), VICOPROFEN (ORAL), XODOL (ORAL), ZAMICET (ORAL), ZOLVIT (ORAL), ZYDONE (ORAL) Androgenic Agents Kathy Novak stated there were no significant clinical updated for this class. Emmett Sullivan motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ANDROGEL GEL PACKET (TRANSDERM.), ANDROGEL GEL PUMP (TRANSDERM), TESTIM (TRANSDERM.) OFF Medicaid PDL: ANDRODERM (TRANSDERM), AXIRON (TRANSDERM), FORTESTA (TRANSDERM) Angiotensin Modulator Combinations Kathy Novak informed committee that Valturna has been discontinued by Novartis. Kevin Chamberlin motioned to accept the recommendations as presented. Emmett Sullivan seconded, and the committee passed the motion unanimously. ON Medicaid PDL: AZOR (ORAL), EXFORGE (ORAL), EXFORGE HCT (ORAL), LOTREL (ORAL), TRIBENZOR (ORAL) OFF Medicaid PDL: AMLODIPINE / BENAZEPRIL (ORAL), AMTURNIDE (ORAL), TARKA (ORAL), TEKAMLO (ORAL), TWYNSTA (ORAL) Angiotensin Modulators Kathy Novak informed that FDA added a fetal toxicity boxed warning to all ACE inhibitors, ARBs, and aliskiren-containing products, and that most are now pregnancy category D. New generics are available for Diovan HCT (valsartan/hctz) and Atacand HCT (candesartan/hctz). Emmett Sullivan motioned to

10 accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: BENAZEPRIL (ORAL), BENAZEPRIL HCTZ (ORAL), CAPTOPRIL (ORAL), CAPTOPRIL HCTZ (ORAL), DIOVAN (ORAL), DIOVAN HCT (ORAL), ENALAPRIL (ORAL), ENALAPRIL HCTZ (ORAL, LISINOPRIL (ORAL), LISINOPRIL HCTZ (ORAL), LOSARTAN (ORAL), LOSARTAN HCTZ (ORAL), MOEXIPRIL (ORAL), MOEXIPRIL HCTZ (ORAL), QUINAPRIL (ORAL), QUINAPRIL HCTZ (ORAL), RAMIPRIL (ORAL) OFF Medicaid PDL: ACCUPRIL (ORAL), ACEON (ORAL), ALTACE (ORAL), ATACAND (ORAL), ATACAND HCT (ORAL), AVALIDE (ORAL), AVAPRO (ORAL), BENICAR (ORAL), BENICAR HCT (ORAL), CANDESARTAN HCTZ (ORAL), COZAAR (ORAL), EDARBI (ORAL), EDARBYCLOR (ORAL), EPROSARTAN (ORAL), FOSINOPRIL (ORAL), FOSINOPRIL HCTZ (ORAL), HYZAAR (ORAL), IRBESARTAN (ORAL), IRBESARTAN HCTZ (ORAL), MAVIK (ORAL), MICARDIS (ORAL), MICARDIS HCT (ORAL, PERINDOPRIL (ORAL), PRINIVIL (ORAL), TEKTURNA (ORAL), TEKTURNA HCT (ORAL), TEVETEN (ORAL), TEVETEN HCT (ORAL), TRANDOLAPRIL (ORAL), UNIRETIC (ORAL), UNIVASC (ORAL), VALSARTAN HCTZ (ORAL), VASOTEC (ORAL), ZESTORETIC (ORAL), ZESTRIL (ORAL) Antibiotics, GI Kathy Novak informed committee that vancomycin oral now has indication for c. difficile associated diarrhea. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded, and the committee passed the motion unanimously. ON Medicaid PDL: METRONIDAZOLE TABLET (ORAL), NEOMYCIN (ORAL), VANCOCIN HCL (ORAL) OFF Medicaid PDL: ALINIA SUSPENSION (ORAL), ALINIA TABLET (ORAL), DIFICID TABLET (ORAL), FLAGYL CAPSULE (ORAL), FLAGYL ER (ORAL), FLAGYL TABLET (ORAL), METRONIDAZOLE CAPSULE (ORAL), TINDAMAX (ORAL), TINIDAZOLE (ORAL), VANCOMYCIN HCL (ORAL), XIFAXAN (ORAL) Antibiotics, Topical Kathy Novak informed committee of new generic mupirocin (Bactroban cream). Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: BACTROBAN OINTMENT (TOPICAL), GENTAMICIN CREAM (TOPICAL) GENTAMICIN OINTMENT (TOPICAL), NEOMYCIN / POLYMYXIN / PRAMOXINE (TOPICAL) OFF Medicaid PDL: ALTABAX (TOPICAL), BACTROBAN CREAM (TOPICAL), CENTANY KIT (TOPICAL), MUPIROCIN CREAM (TOPICAL), MUPIROCIN OINTMENT (TOPICAL) Antibiotics, Vaginal There were no significant clinical updates for this medication class. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously.

11 ON Medicaid PDL: CLEOCIN OVULES (VAGINAL), CLINDAMYCIN (VAGINAL), METROGEL- VAGINAL (VAGINAL), VANDAZOLE (VAGINAL) OFF Medicaid PDL: CLEOCIN CREAM (VAGINAL), METRONIDAZOLE (VAGINAL) Antifungals, Oral Kathy Novak informed committee of new medication to class, Onmel (itraconazole). Dr. Charles Thompson motioned to accept the recommendations as presented for this class. Dr. Hilda Slivka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: CLOTRIMAZOLE (MUCOUS MEM), FLUCONAZOLE SUSPENSION (ORAL), FLUCONAZOLE TABLET (ORAL), GRISEOFULVIN SUSPENSION (ORAL), GRIS-PEG (ORAL), KETOCONAZOLE (ORAL), NYSTATIN SUSPENSION (ORAL), TERBINAFINE (ORAL) OFF Medicaid PDL: DIFLUCAN SUSPENSION (ORAL), DIFLUCAN TABLET (ORAL), FLUCYTOSINE (ORAL), GRIFULVIN V TABLETS (ORAL), GRISEOFULVIN TABLETS (ORAL), GRISEOFULVIN ULTRAMICROSIZE (ORAL), ITRACONAZOLE (ORAL), LAMISIL GRANULES (ORAL), LAMISIL TABLET (ORAL), NOXAFIL (ORAL), NYSTATIN POWDER (ORAL), NYSTATIN TABLET (ORAL), ONMEL (ORAL), SPORANOX CAPSULE (ORAL), SPORANOX SOLUTION (ORAL), TERBINEX KIT (MISCELL), VFEND SUSPENSION (ORAL), VFEND TABLET (ORAL), VORICONAZOLE TABLETS (ORAL) Antifungals, Topical There were no significant clinical updates for this category from Provider Synergies. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: CLOTRIMAZOLE CREAM RX (TOPICAL), CLOTRIMAZOLE SOLUTION RX (TOPICAL), CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL), CLOTRIMAZOLE- BETAMETHASONE LOTION (TOPICAL), ECONAZOLE (TOPICAL), KETOCONAZOLE CREAM (TOPICAL), KETOCONAZOLE SHAMPOO (TOPICAL), NYSTATIN CREAM (TOPICAL), NYSTATIN OINT (TOPICAL), NYSTATIN POWDER (TOPICAL), NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL), NYSTATIN-TRIAMCINOLONE OINT (TOPICAL) OFF Medicaid PDL: BENSAL HP (TOPICAL), CICLODAN CREAM (TOPICAL), CICLODAN KIT (TOPICAL), CICLOPIROX CREAM (TOPICAL), CICLOPIROX GEL (TOPICAL), CICLOPIROX KIT (TOPICAL), CICLOPIROX SHAMPOO (TOPICAL), CICLOPIROX SOLUTION (TOPICAL), CICLOPIROX SUSPENSION (TOPICAL), CNL 8 KIT (TOPICAL), ERTACZO (TOPICAL), EXELDERM CREAM (TOPICAL), EXELDERM SOLUTION (TOPICAL), EXTINA (TOPICAL), KETOCONAZOLE FOAM (TOPICAL), KETODAN FOAM (TOPICAL), KETODAN FOAM KIT (TOPICAL), LOPROX GEL (TOPICAL), LOPROX SHAMPOO (TOPICAL), LOTRISONE CREAM (TOPICAL), MENTAX (TOPICAL), NAFTIN CREAM (TOPICAL), NAFTIN GEL (TOPICAL), NIZORAL SHAMPOO (TOPICAL), OXISTAT CREAM (TOPICAL), OXISTAT LOTION (TOPICAL), PEDIADERM AF (TOPICAL), PEDIPIROX-4 (TOPICAL), PENLAC (TOPICAL), VUSION (TOPICAL), XOLEGEL (TOPICAL) Antimigraine Agents

12 Provider Synergies did not have any significant clinical updates for this class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded, and the committee passed the motion unanimously. ON Medicaid PDL: IMITREX (NASAL), IMITREX KIT (SUBCUTANE.), IMITREX VIAL (SUBCUTANE.), RELPAX (ORAL), SUMATRIPTAN (ORAL), SUMATRIPTAN KIT (SUBCUTANE.), SUMATRIPTAN KIT (SUN) (SUBCUTANE.) OFF Medicaid PDL: ALSUMA (SUBCUTANEOUS), AMERGE (ORAL), AXERT (ORAL), CAMBIA (ORAL), FROVA (ORAL), IMITREX (ORAL), MAXALT MLT (ORAL), MAXALT TABLET (ORAL), NARATRIPTAN (ORAL), RIZATRIPTAN ODT (ORAL), RIZATRIPTAN TABLET (ORAL), SUMATRIPTAN (NASAL), SUMATRIPTAN VIAL (SUBCUTANE.), SUMAVEL DOSEPRO (SUBCUTANE.), TREXIMET (ORAL), ZOMIG (NASAL), ZOMIG (ORAL), ZOMIG ZMT (ORAL) Antivirals, Oral Kathy Novak informed the committee that Tamiflu now has an indication for uncomplicated influenza infection down to two weeks of age. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ACYCLOVIR CAPSULE (ORAL), ACYCLOVIR SUSPENSION (ORAL), ACYCLOVIR TABLET (ORAL), AMANTADINE CAPSULE (ORAL), AMANTADINE SYRUP (ORAL), RELENZA (INHALATION), RIMANTADINE (ORAL), TAMIFLU CAPSULE (ORAL), TAMIFLU SUSPENSION (ORAL), VALACYCLOVIR (ORAL) OFF Medicaid PDL: AMANTADINE TABLET (ORAL), FAMCICLOVIR (ORAL), FAMVIR (ORAL), VALTREX (ORAL), ZOVIRAX SUSPENSION (ORAL), ZOVIRAX TABLET (ORAL) Antivirals, Topical Kathy Novak advised there were no significant clinical updates for this class. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded, and the committee passed the motion unanimously. ON Medicaid PDL: DENAVIR (TOPICAL), ZOVIRAX OINTMENT (TOPICAL) OFF Medicaid PDL: XERESE (TOPICAL), ZOVIRAX CREAM (TOPICAL) Beta-Blockers Kathy Novak advised there were no significant clinical updates for this class. Dr. Charles Thompson motioned to accept the recommendations as presented for this class. Dr. Manage Nissanka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ACEBUTOLOL (ORAL), ATENOLOL (ORAL), ATENOLOL / CHLORTHALIDONE (ORAL), BETAXOLOL (ORAL), BISOPROLOL (ORAL), CARVEDILOL (ORAL), LABETALOL (ORAL),

13 METOPROLOL (ORAL), NADOLOL (ORAL), NADOLOL / BENDROFLUMETHIAZIDE (ORAL), PROPRANOLOL / HCTZ (ORAL), PROPRANOLOL ER (ORAL), PROPRANOLOL SOLUTION (ORAL), PROPRANOLOL TABLET (ORAL), SOTALOL (ORAL), TIMOLOL (ORAL), TOPROL XL (ORAL) OFF Medicaid PDL: BETAPACE / AF (ORAL), BISOPROLOL HCTZ (ORAL), BYSTOLIC (ORAL), COREG (ORAL), COREG CR (ORAL), CORGARD (ORAL), CORZIDE (ORAL), DUTOPROL (ORAL), INDERAL LA (ORAL), INNOPRAN XL (ORAL), LEVATOL (ORAL), METOPROLOL / HCTZ (ORAL), METOPROLOL XL (ORAL), PINDOLOL (ORAL), SECTRAL (ORAL), TENORETIC (ORAL), TENORMIN (ORAL), ZIAC (ORAL) BPH Treatments Kathy Novak advised there were no significant clinical updates for this class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Kevin Chamberlin seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ALFUZOSIN (ORAL), DOXAZOSIN (ORAL), FINASTERIDE (ORAL), TAMSULOSIN (ORAL), TERAZOSIN (ORAL) OFF Medicaid PDL: AVODART (ORAL), CARDURA (ORAL), CARDURA XL (ORAL), CIALIS (ORAL), FLOMAX (ORAL), JALYN (ORAL), PROSCAR (ORAL), RAPAFLO (ORAL), UROXATRAL (ORAL) Calcium Channel Blockers Kathy Novak advised there were no significant clinical updates for this class. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: AMLODIPINE (ORAL), DILTIAZEM CAPSULE ER (ORAL), DILTIAZEM TABLET (ORAL), NICARDIPINE (ORAL), NIFEDIPINE ER (ORAL), VERAPAMIL CAPSULE (ORAL), VERAPAMIL ER PM (ORAL), VERAPAMIL TABLET (ORAL), VERAPAMIL TABLET ER (ORAL) OFF Medicaid PDL: ADALAT CC (ORAL), CALAN SR (ORAL), CARDENE SR (ORAL), CARDIZEM CD (ORAL), CARDIZEM CD 360 MG (ORAL), CARDIZEM LA (ORAL), DILTIAZEM LA (ORAL), FELODIPINE ER (ORAL), ISRADIPINE (ORAL), MATZIM LA (ORAL), NIFEDIPINE IR (ORAL), NIMODIPINE (ORAL), NISOLDIPINE (ORAL), NORVASC (ORAL), PROCARDIA (ORAL), PROCARDIA XL (ORAL), SULAR (ORAL), TIAZAC (ORAL), TIAZAC 420 MG (ORAL), VERAPAMIL 360 MG CAPSULE (ORAL), VERELAN (ORAL), VERELAN PM (ORAL) Cephalosporins and Related Antibiotics Kathy Novak advised there were no significant clinical updates for this class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: AMOXICILLIN/CLAV CHEW TABLET (ORAL), AMOXICILLIN/CLAV SUSPENSION (ORAL), AMOXICILLIN/CLAV TABLET (ORAL), CEFACLOR CAPSULE (ORAL), CEFACLOR SUSPENSION (ORAL), CEFACLOR TABLET ER (ORAL), CEFADROXIL CAPSULE (ORAL),

14 CEFADROXIL SUSPENSION (ORAL), CEFADROXIL TABLET (ORAL), CEFDINIR CAPSULE (ORAL), CEFDINIR SUSPENSION (ORAL), CEFPODOXIME SUSPENSION (ORAL), CEFPODOXIME TABLET (ORAL), CEFPROZIL SUSPENSION (ORAL), CEFPROZIL TABLET (ORAL), CEFUROXIME SUSPENSION (ORAL), CEFUROXIME TABLET (ORAL), CEPHALEXIN CAPSULE (ORAL), CEPHALEXIN SUSPENSION (ORAL), CEPHALEXIN TABLET (ORAL), SUPRAX SUSPENSION (ORAL), SUPRAX TABLET (ORAL) OFF Medicaid PDL: AMOXICILLIN/CLAV XR (ORAL), AUGMENTIN 125 SUSPENSION (ORAL), AUGMENTIN 250 SUSPENSION (ORAL), AUGMENTIN TABLET (ORAL), AUGMENTIN XR (ORAL), CEDAX CAPSULE (ORAL), CEDAX SUSPENSION (ORAL), CEFDITOREN (ORAL), CEFTIN SUSPENSION (ORAL), CEFTIN TABLET (ORAL), KEFLEX 250, 500 MG CAPSULE (ORAL), KEFLEX 750 MG CAPSULE (ORAL), SPECTRACEF (ORAL), SUPRAX TAB CHEW (ORAL) Contraceptives, Oral Kathy Novak advised there were no significant clinical updates for this class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Hilda Slivka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ALYACEN (ORAL), AVIANE (ORAL), BREVICON (ORAL), BRIELLYN (ORAL), CAMILA (ORAL), CAMRESE (ORAL), CHATEAL (ORAL), CRYSELLE (ORAL), CYCLAFEM (ORAL), DASETTA (ORAL), ELINEST (ORAL), ENPRESSE (ORAL) FALMINA (ORAL), FEMCON FE (ORAL), GILDESS (ORAL), GILDESS FE (ORAL), HEATHER (ORAL), JUNEL (ORAL), JUNEL FE (ORAL), KARIVA (ORAL), KURVELO (ORAL), LESSINA (ORAL), LEVONEST (ORAL), LOESTRIN (ORAL), LOESTRIN FE (ORAL), LOSEASONIQUE (ORAL), LOW-OGESTREL (ORAL), LUTERA (ORAL), MICROGESTIN (ORAL), MICROGESTIN FE (ORAL), MIRCETTE (ORAL), MYZILRA (ORAL), NECON (ORAL), NORDETTE-28 (ORAL), NORETHINDRONE (ORAL), NORETHINDRONE-ETHIN ESTRADIOL (ORAL), NORGESTIMATE-ETHINYL ESTRADIOL (ORAL), NORINYL 1+50 (ORAL), NORTREL (ORAL), ORSYTHIA (ORAL), ORTHO TRI-CYCLEN LO (ORAL), OVCON-35 (ORAL), OVCON-50 (ORAL), PHILITH (ORAL), SEASONALE (ORAL), SEASONIQUE (ORAL), TRI-LINYAH (ORAL), TRI- PREVIFEM (ORAL), TRI-SPRINTEC (ORAL), TRIVORA-28 (ORAL), VIORELE (ORAL), WERA (ORAL), YASMIN 28 (ORAL), YAZ (ORAL), ZENCHENT (ORAL) OFF Medicaid PDL: ALTAVERA (ORAL), AMETHIA (ORAL), AMETHYST (ORAL), APRI (ORAL), ARANELLE (ORAL), AZURETTE (ORAL), BALZIVA (ORAL), BEYAZ (ORAL), CAZIANT (ORAL), CYCLESSA (ORAL), DESOGEN (ORAL), EMOQUETTE (ORAL), ERRIN (ORAL), ESTROSTEP FE (ORAL), ETHINYL ESTRADIOL/DROSPIRENONE (ORAL), GENERESS FE (ORAL), GIANVI (ORAL), GILDAGIA (ORAL), INTROVALE (ORAL), JOLESSA (ORAL), JOLIVETTE (ORAL), KELNOR 1-35 (ORAL), LEENA (ORAL), LEVORA-28 (ORAL), L-NORGEST-ETH ESTR/ETHIN ESTRA (ORAL), LO LOESTRIN FE (ORAL), LOESTRIN 24 FE (ORAL), MARLISSA (ORAL), MICRONOR (ORAL), MODICON (ORAL), MONO-LINYAH (ORAL), MONONESSA (ORAL), NATAZIA (ORAL), NORA-BE (ORAL), NORINYL 1+35 (ORAL), NOR-Q-D (ORAL), OCELLA (ORAL), OGESTREL (ORAL), ORTHO TRI-CYCLEN (ORAL), ORTHO-CEPT (ORAL), ORTHO-CYCLEN (ORAL), ORTHO-NOVUM (ORAL), PORTIA (ORAL), PREVIFEM (ORAL), QUASENSE (ORAL), RECLIPSEN (ORAL), SAFYRAL (ORAL), SPRINTEC (ORAL), SRONYX (ORAL), SYEDA (ORAL), TILIA FE (ORAL), TRI-LEGEST FE (ORAL), TRINESSA (ORAL), TRI-NORINYL (ORAL), VELIVET (ORAL), WYMZYA FE (ORAL), ZARAH (ORAL), ZOVIA 1-35E (ORAL), ZOVIA 1-50E (ORAL)

15 Fluoroquinolones, Oral Kathy Novak informed committee that Levofloxacin now has indication for treatment of plague. Dr. Hilda Slivka commented on the lack of an oral suspension in the recommendations for the PDL. She noted that despite age restrictions this class is used in pediatric populations. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class along with the addition of Cipro oral suspension. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: CIPRO SUSPENSION (ORAL), CIPROFLOXACIN TABLET (ORAL), LEVOFLOXACIN TABLET (ORAL) OFF Medicaid PDL: AVELOX (ORAL), CIPRO TABLET (ORAL), CIPROFLOXACIN ER (ORAL), FACTIVE (ORAL), LEVAQUIN SOLUTION (ORAL), LEVAQUIN TABLET (ORAL), LEVOFLOXACIN SOLUTION (ORAL), NOROXIN (ORAL), OFLOXACIN (ORAL) Growth Factors Kathy Novak advised there were no significant clinical updates for this class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Hilda Slivka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: EGRIFTA (SUB-Q), INCRELEX (SUB-Q) OFF Medicaid PDL: NONE H. Pylori Treatments Kathy Novak advised there were no significant clinical updates for this class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Carl Sherter seconded, and the committee passed the motion unanimously. ON Medicaid PDL: NONE OFF Medicaid PDL: HELIDAC (ORAL), OMECLAMOX-PAK (ORAL), PREVPAC (ORAL), PYLERA (ORAL) Hypoglycemics, Meglitinides Kathy Novak advised there were no significant clinical updates for this class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Manage Nissanka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: NATEGLINIDE (ORAL), PRANDIN (ORAL) OFF Medicaid PDL: PRANDIMET (ORAL), STARLIX (ORAL) Hypoglycemics, TZD

16 Kathy Novak advised group of new generics pioglitazone (Actos) and pioglitazone/metformin (Actoplus Met). Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: PIOGLITAZONE (ORAL) OFF Medicaid PDL: ACTOPLUS MET (ORAL), ACTOPLUS MET XR (ORAL), ACTOS (ORAL), AVANDAMET (ORAL), AVANDARYL (ORAL), AVANDIA (ORAL), DUETACT (ORAL), PIOGLITAZONE / METFORMIN (ORAL), PIOGLITAZONE/GLIMEPIRIDE (ORAL) Immunosuppressives, Oral Kathy Novak informed committee of REMS program added to Mycophenolate. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Manage Nissanka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: AZATHIOPRINE (ORAL), CYCLOSPORINE CAPSULE (ORAL), CYCLOSPORINE SOFTGEL (ORAL), CYCLOSPORINE, MODIFIED CAPSULE (ORAL), CYCLOSPORINE, MODIFIED SOLUTION (ORAL), MYCOPHENOLATE MOFETIL CAPSULE (ORAL), MYCOPHENOLATE MOFETIL TABLET (ORAL), NEORAL CAPSULE (ORAL), NEORAL SOLUTION (ORAL), RAPAMUNE SOLUTION (ORAL), RAPAMUNE TABLET (ORAL), SANDIMMUNE CAPSULE (ORAL), SANDIMMUNE SOLUTION (ORAL), TACROLIMUS (ORAL) OFF Medicaid PDL: AZASAN (ORAL), CELLCEPT CAPSULE (ORAL), CELLCEPT SUSPENSION (ORAL), CELLCEPT TABLET (ORAL), IMURAN (ORAL), MYFORTIC (ORAL), PROGRAF (ORAL), ZORTRESS (ORAL) Lipotropics, Other No new clinical updates were presented for this class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Karen McMillan seconded, and the committee passed the motion unanimously. ON Medicaid PDL: CHOLESTYRAMINE/ASPARTAME (ORAL), CHOLESTYRAMINE/SUCROSE (ORAL), GEMFIBROZIL (ORAL), NIACOR (ORAL), NIASPAN (ORAL), TRICOR (ORAL), TRILIPIX (ORAL) OFF Medicaid PDL: ANTARA (ORAL), COLESTID GRANULES (ORAL), COLESTID TABLET (ORAL), COLESTIPOL GRANULES (ORAL), COLESTIPOL TABLET (ORAL), FENOFIBRATE (ANTARA) (ORAL), FENOFIBRATE CAPSULE (LOFIBRA) (ORAL), FENOFIBRATE TABLET (AG) (TRICOR) (ORAL), FENOFIBRATE TABLET (LOFIBRA) (ORAL), FENOFIBRATE TABLET (TRICOR) (ORAL), FENOFIBRIC ACID (ORAL), FIBRICOR (ORAL), LIPOFEN (ORAL), LOPID (ORAL), LOVAZA (ORAL), QUESTRAN (ORAL), QUESTRAN LIGHT (ORAL), TRIGLIDE (ORAL), VASCEPA (ORAL), WELCHOL POWDER PACK (ORAL), WELCHOL TABLET (ORAL), ZETIA (ORAL) Lipotropics, Statins No new clinical updates from Provider Synergies were presented. The committee discussed the recommendation to remove atorvastatin from the PDL and the inclusion of rosuvastatin. Dr. Sherter noted the difference in side effect profile for these agents and that patients could experience side

17 effects if switching product. Dr. Cynthia Conrad motioned to accept the recommendations as presented for this class along with Atorvastatin. Dr. Manage Nissanka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ATORVASTATIN (ORAL), CRESTOR (ORAL), LESCOL (ORAL), LESCOL XL (ORAL), LOVASTATIN (ORAL), PRAVASTATIN (ORAL), SIMCOR (ORAL), SIMVASTATIN (ORAL) OFF Medicaid PDL: ADVICOR (ORAL), ALTOPREV (ORAL), AMLODIPINE-ATORVASTATIN (ORAL), CADUET (ORAL), FLUVASTATIN (ORAL), LIPITOR (ORAL), LIVALO (ORAL), PRAVACHOL (ORAL), VYTORIN (ORAL), ZOCOR (ORAL) Macrolides/Ketolides Kathy Novak advised there were no significant clinical updates for this class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: AZITHROMYCIN PACKET (ORAL), AZITHROMYCIN SUSPENSION (ORAL), AZITHROMYCIN TABLET (ORAL), CLARITHROMYCIN TABLET (ORAL), E.E.S. 400 TABLET (ORAL), ERY-TAB (ORAL), ERYTHROCIN (ORAL), ERYTHROMYCIN BASE TABLET (ORAL) OFF Medicaid PDL: BIAXIN SUSPENSION (ORAL), BIAXIN TABLET (ORAL), CLARITHROMYCIN ER (ORAL), CLARITHROMYCIN SUSPENSION (ORAL), E.E.S. 200 SUSPENSION (ORAL), ERYPED 200 SUSPENSION (ORAL), ERYPED 400 SUSPENSION (ORAL), ERYTHROMYCIN BASE CAPSULE DR (ORAL), KETEK (ORAL), PCE (ORAL), ZITHROMAX PACKET (ORAL), ZITHROMAX SUSPENSION (ORAL), ZITHROMAX TABLET (ORAL), ZMAX (ORAL) Phosphate Binders Kathy Novak advised there were no significant clinical updates for this class. Dr. Charles Thompson motioned to accept the recommendations as presented for this class. Dr. Hilda Slivka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: CALCIUM ACETATE CAPSULE (ORAL), CALCIUM ACETATE TABLET (ORAL), ELIPHOS (ORAL), RENAGEL (ORAL) OFF Medicaid PDL: FOSRENOL (ORAL), MAGNEBIND 400 RX (ORAL), PHOSLO (ORAL), PHOSLYRA (ORAL), RENVELA POWDER PACK (ORAL), RENVELA TABLET (ORAL) Pituitary Suppressive Agents, LNRH Kathy Novak informed committee this is a new class of medications for review. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: LEUPROLIDE ACETATE (SUB-Q), LUPRON DEPOT (INTRAMUSC), LUPRON DEPOT KIT (INJECTION), LUPRONJ DEPOT-PED (INJECTION), LUPRONJ DEPOT-PED KIT (INJECTION), ZOLADEX (SUB-Q)

18 OFF Medicaid PDL: ELIGARD (SUB-Q), SUPPRELIN LA KIT (IMPLANT), SYNAREL (NASAL), TRELSTAR (INTRAMUSC), TRELSTAR DEPOT (INTRAMUSC), TRELSTAR LA (INTRAMUSC), VANTAS KIT (IMPLANT) Prenatal Vitamins There were no new clinical updates discussed for this class. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: B-NEXA (ORAL), CA CARBONATE/VIT B12/FA/VIT B6 (ORAL), CAVAN-ALPHA KIT (ORAL), CENTRUM SPECIALIST PRENATAL OTC (ORAL), CITRANATAL 90 DHA (ORAL), CITRANATAL ASSURE (ORAL), CITRANATAL B-CALM (ORAL), CITRANATAL HARMONY (ORAL), CITRANATAL RX (ORAL), COMPLETE NATAL DHA (ORAL), COMPLETENATE (ORAL), CONCEPT DHA (ORAL), CONCEPT OB (ORAL), DAILY PRENATAL (ORAL), EZFE FORTE (ORAL), FE C (ORAL), FOLIVANE-OB (ORAL), FOLIVANE-PRX DHA NF (ORAL), ICAR-C PLUS (ORAL), LEVOMEFOLATE DHA (ORAL), MARNATAL-F (ORAL), MATERNITY (ORAL), MAXINATE (ORAL), MINI PRENATAL OTC (ORAL), M-VIT (ORAL), MYNATAL (ORAL), MYNATAL PLUS (ORAL), MYNATAL-Z (ORAL), NATAFORT (ORAL), NATALVIRT 90 DHA (ORAL), NATALVIRT CA (ORAL), NATALVIT (ORAL), NATELLE-EZ OTC (ORAL), NESTABS (ORAL), NESTABS DHA (ORAL), NEXA SELECT (ORAL), OB COMPLETE 400 (ORAL), OB COMPLETE WITH DHA (ORAL), O-CAL FA (ORAL), O-CAL PRENATAL (ORAL), ONE-A-DAY WOMEN'S PRENATAL DHA OTC (ORAL), PNV 87/IRON BISGLY/FA/DHA (ORAL), PNV NO.22/IRON CBN&GLUC/FA/DSS (ORAL), PNV WITH CA,NO.71/IRON/FA (ORAL), PNV WITH CA,NO.72/IRON,CARB/FA (ORAL), PNV WITH CA,NO.72/IRON/FA (ORAL), PNV WITH CA,NO.74/IRON/FA BRAND (ORAL), PNV66/IRON FUMARATE/FA/DSS/DHA (ORAL), PNV69/IRON,CARBONYL/FA/DSS/DHA OTC (ORAL), PNV80/IRON FUMARATE/FA/DSS/DHA (ORAL), PNV81/SOD IRON EDTA& PS/FA/OM3 (ORAL), PR NATAL 400 (ORAL), PR NATAL 430 (ORAL), PREFERA OB (ORAL), PREFERA-OB ONE (ORAL), PREFERA-OB PLUS DHA (ORAL), PRENAISSANCE BALANCE (ORAL), PRENAISSANCE NEXT (ORAL), PRENATA (ORAL), PRENATABS RX (ORAL), PRENATAL MULTI + DHA OTC (ORAL), PRENATAL ONE OTC (ORAL), PRENATAL RX (ORAL), PRENATAL VIT 15/IRON CB/FA/DSS (ORAL), PRENATAL VIT 18/IRON CB/FA/DSS (ORAL), PRENATAL VIT 86/IRON BISGLY/FA (ORAL), PRENATAL VIT/FE FUMARATE/FA OTC (ORAL), PRENATAL VIT27&CALCIUM/IRON/FA (ORAL), PRENATAL VITAMIN + DHA OTC (ORAL), PRENATAL VITAMINS OTC (ORAL), PRENATAL VITS W-CA,FE,FA(LT1MG) OTC (ORAL), PRENEXA (ORAL), PROFE FORTE OTC (ORAL), PUREFE OB PLUS (ORAL), PUREFE PLUS (ORAL), PV W-O VIT A/FE FUMARATE/FA (ORAL), SELECT-OB (ORAL), SELECT-OB + DHA (ORAL), SE-NATAL 19 TAB CHEW (ORAL), SE-NATAL 19 TABLET (ORAL), SE-TAN DHA (ORAL), SETONET (ORAL), SIMILAC PRENATAL OTC (ORAL), TARON-BC (ORAL), TARON-C DHA (ORAL), TL-SELECT DHA (ORAL), TRINATAL GT (ORAL), TRIVEEN-DUO DHA (ORAL), TRIVEEN-PRX RNF (ORAL), TRIVEEN-U (ORAL), TRUST NATAL DHA (ORAL), ULTIMATE OB DHA (ORAL), ULTIMATECARE ONE NF (ORAL), VINATE AZ (ORAL), VINATE CALCIUM (ORAL), VINATE DHA OTC (ORAL), VINATE GT (ORAL), VINATE IC (ORAL), VINATE II (ORAL), VINATE PN CARE (ORAL), VINATE-M (ORAL), VITAFOL-OB (ORAL), VITAFOL-OB+DHA (ORAL), VITAFOL-ONE (ORAL), V- NATAL (ORAL), V-NATAL DHA (ORAL), VOL-NATE (ORAL), VOL-TAB RX (ORAL), VP-CH-PNV (ORAL), VP-ERA OB PLUS (ORAL), VP-GGR-B6 (ORAL), VYNATAL-FA (ORAL), ZATEAN-CH (ORAL), ZATEAN-PN DHA (ORAL), ZINGIBER (ORAL) OFF Medicaid PDL: BAL-CARE DHA ESSENTIAL (ORAL), CAVAN-EC SOD DHA (ORAL), CITRANATAL DHA (ORAL), DUET DHA (ORAL), DUET DHA BALANCED (ORAL), DUET DHA EC (ORAL), ELITE-OB (ORAL), EXTRA-VIRT PLUS DHA (ORAL), GESTICARE DHA (ORAL), HEMENATAL OB (ORAL), HEMENATAL OB + DHA (ORAL), L-METHYLFOLATE PNV DHA (ORAL), NATA KOMPLETE (ORAL), NATACHEW TAB CHEW (ORAL), NATELLE ONE (ORAL), NEEVO DHA (ORAL), NEXA PLUS (ORAL), OB COMPLETE ONE (ORAL), OB COMPLETE PETITE (ORAL), OB COMPLETE PREMIER (ORAL), OB COMPLETE TAB CHEW (ORAL), OB COMPLETE TABLET

19 (ORAL), PAIRE OB PLUS DHA (ORAL), PNV OB+DHA (ORAL), PNV W-CA NO.37/IRON/FA/OMEGA- 3 (ORAL), PNV W-CA NO.40/IRON FUM/FA CMB NO.1 (ORAL), PNV WITH CA NO.68/IRON/FA NO.1/DHA (ORAL), PNV17/IRON/FA/FISH OIL/DHA/OM (ORAL), PNV-DHA (ORAL), PNV-DHA PLUS (ORAL), PNV-IRON (ORAL), PR NATAL 400 EC (ORAL), PR NATAL 430 EC (ORAL), PRENAISSANCE HARMONY DHA (ORAL), PRENATE CHEWABLE (ORAL), PRENATE MINI (ORAL), PREQUE 10 (ORAL), RELNATE DHA (ORAL), SETONET-EC (ORAL), TARON-DUO EC (ORAL), TARON-PREX PRENATAL (ORAL), TL-ASSURE + DHA (ORAL), TL-ASSURE ONE (ORAL), TRICARE (ORAL), TRICARE DHA (ORAL), TRIVEEN-TEN (ORAL), VIRT-BAL DHA (ORAL), VIRT- BAL DHA PLUS (ORAL), VIRT-PN (ORAL), VIRT-PN DHA (ORAL), VITAFOL-PN (ORAL), VIVA CT (ORAL), VIVA DHA (ORAL), VP-PNV-DHA (ORAL) Proton Pump Inhibitors Kathy Novak advised there were no significant clinical updates for this class. Dr. Hilda Slivka motioned to accept the recommendations along with the addition of Prevacid Solutabs carrying an age restriction for 0-20 years. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: PANTOPRAZOLE (ORAL), PREVACID SOLUTAB (ORAL), PRILOSEC OTC (ORAL), PROTONIX SUSPENSION (ORAL) OFF Medicaid PDL: ACIPHEX (ORAL), DEXILANT (ORAL), LANSOPRAZOLE CAPSULES (ORAL), LANSOPRAZOLE CAPSULES OTC (ORAL), LANSOPRAZOLE SOLUTAB (ORAL), LANSOPRAZOLE SUSPENSION (ORAL), NEXIUM (ORAL), NEXIUM SUSPENSION (ORAL), OMEPRAZOLE (ORAL), OMEPRAZOLE / SODIUM BICARBONATE (ORAL), OMEPRAZOLE / SODIUM BICARBONATE OTC (ORAL), OMEPRAZOLE MAGNESIUM OTC (ORAL), OMEPRAZOLE OTC (ORAL), OMEPRAZOLE SUSPENSION (ORAL), PREVACID CAPSULES (ORAL), PREVACID CAPSULES OTC (ORAL), PRILOSEC (ORAL), PRILOSEC SUSPENSION (ORAL), PROTONIX (ORAL), ZEGERID (ORAL), ZEGERID OTC (ORAL) Skeletal Muscle Relaxants There were no clinical updates discussed for this medication class. Kevin Chamberlin motioned to accept the recommendations as presented for this class. Dr. Hilda Slivka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: BACLOFEN (ORAL), CHLORZOXAZONE (ORAL), CYCLOBENZAPRINE (ORAL), METHOCARBAMOL (ORAL) OFF Medicaid PDL: AMRIX (ORAL), CARISOPRODOL (ORAL), CARISOPRODOL 250 MG (ORAL), CARISOPRODOL COMPOUND (ORAL), CYCLOBENZAPRINE ER (ORAL), DANTRIUM (ORAL), DANTROLENE SODIUM (ORAL), FEXMID (ORAL), LORZONE (ORAL), METAXALONE (ORAL), ORPHENADRINE (ORAL), ORPHENADRINE COMPOUND (ORAL), ROBAXIN (ORAL), SKELAXIN (ORAL), SOMA (ORAL), SOMA 250 MG (ORAL), TIZANIDINE CAPSULES (ORAL), TIZANIDINE TABLETS (ORAL), ZANAFLEX CAPSULE (ORAL), ZANAFLEX TABLET (ORAL) Tetracyclines Kathy Novak advised there were no significant clinical updates for this class. Dr. Manage Nissanka motioned to accept the recommendations as presented for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously.

20 ON Medicaid PDL: DOXYCYCLINE HYCLATE CAPSULE (ORAL), DOXYCYCLINE HYCLATE TABLET (ORAL), DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL), DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL), MINOCYCLINE CAPSULES (ORAL), TETRACYCLINE (ORAL) OFF Medicaid PDL: ADOXA CAPSULE (ORAL), DEMECLOCYCLINE (ORAL), DORYX (ORAL), DOXYCYCLINE HYCLATE TABLET DR (ORAL), DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL), DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL), DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL), DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL), DOXYCYCLINE MONOHYDRATE TABLET (ORAL), MINOCYCLINE ER (ORAL), MINOCYCLINE TABLETS (ORAL), MORGIDOX KIT (MISCELL), ORACEA (ORAL), SOLODYN (ORAL), VIBRAMYCIN CAPSULE (ORAL), VIBRAMYCIN SUSPENSION (ORAL), VIBRAMYCIN SYRUP (ORAL) Ulcerative Colitis Agents There were no new clinical updates discussed for this medication class. Dr. Hilda Slivka stated that Pentasa was the standard of care in this medication class. Dr. Slivka motioned to accept the recommendations along with the addition of Pentasa for this class. Dr. Charles Thompson seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ASACOL (ORAL), CANASA (RECTAL), LIALDA (ORAL), PENTASA (ORAL), SULFASALAZINE (ORAL), SULFASALAZINE DR (ORAL) OFF Medicaid PDL: APRISO (ORAL), ASACOL HD (ORAL), AZULFIDINE TABLET (ORAL), AZULFIDINE TABLET DR (ORAL), BALSALAZIDE (ORAL), COLAZAL (ORAL), DIPENTUM (ORAL), GIAZO (ORAL), MESALAMINE (RECTAL), MESALAMINE KIT (RECTAL), ROWASA (RECTAL), SFROWASA (RECTAL) Vasodilators, Coronary Kathy Novak informed the committee that this was a new medication class for review. No clinical updated were discussed. Dr. Hilda Slivka motioned to accept the recommendations as presented for this class. Dr. Manage Nissanka seconded, and the committee passed the motion unanimously. ON Medicaid PDL: ISOSORBIDE DINITRATE (ORAL), ISOSORBIDE DINITRATE ER (ORAL), ISOSORBIDE MONONITRATE (ORAL), ISOSORBIDE MONONITRATE SR (ORAL), NITROGLYCERIN (SUBLINGUAL), NITROGLYCERIN (TRANSDERM), NITROGLYCERIN (TRANSLINGUAL), NITROGLYCERIN ER (ORAL), NITROLINGUAL SPRAY (TRANSLINGUAL), NITROSTAT (SUBLINGUAL) OFF Medicaid PDL: DILATRATE-SR (ORAL), IMDUR (ORAL), ISORDIL (ORAL), ISOSORBIDE DINITRATE (SUBLINGUAL), NITRO-BID OINT. (TRANSDERM), NITRO-BID PATCH (TRANSDERM), NITROGLYCERIN (TRANSLING), NITROMIST (TRANSLING) Committee Discussion Topics: